

## **Generex Announces Investor Conference Call; Management to Provide Update on Initiatives & Strategic Plans**

MIRAMAR, Florida, December 18, 2017 (BUSINESS WIRE) – Generex Biotechnology Corporation (OTCQB:GNBT) (<http://www.otcmarkets.com/stock/GNBT/quote>) ([www.generex.com](http://www.generex.com)) today announced that it will hold an investor conference call at **10:30 a.m. Eastern time on Thursday, January 4, 2018**. Dial-in instructions will be issued prior to the date of the call.

The purpose of the conference call will be to provide investors with an update on the Company's initiatives and strategic plans, including its capital reorganization, its controlling interest in Hema Diagnostic Systems, LLC ([www.hemadiagnosticsystems.com](http://www.hemadiagnosticsystems.com)), the recently announced initiatives of Antigen Express, Inc. ([www.antigenexpress.com](http://www.antigenexpress.com)), the Company's wholly-owned immuno-therapeutics subsidiary, with Merck Sharp & Dohme B.V. and Shenzhen BioScien Pharmaceuticals Co. Ltd., and the Company's buccal drug delivery platform technologies.

Joseph Moscato, the Generex President & Chief Executive Officer, stated: "2017 has been a very busy, productive, and revitalizing year for Generex. I am looking forward to reviewing this past year with my fellow stockholders and providing a glimpse of what the future holds for our Company."

### **Cautionary Note Regarding Forward-Looking Statements**

*This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.*

SOURCE Generex Biotechnology Corporation

Generex Contact:

Joseph Moscato  
646-599-6222

Generex Biotechnology Corporation  
Todd Falls  
800-391-6755  
Extension 222  
[investor@generex.com](mailto:investor@generex.com)